Psychological disorders
Bipolar disorder
Neuroleptic malignant syndrome
Serotonin syndrome
Body dysmorphic disorder
Body focused repetitive disorders
Obsessive-compulsive disorder
Delusional disorder
Schizoaffective disorder
Schizophrenia
Schizophreniform disorder
Alcohol use disorder
Cannabis dependence
Cocaine dependence
Opioid dependence
Tobacco dependence
Amnesia, dissociative disorders and delirium: Pathology review
Childhood and early-onset psychological disorders: Pathology review
Dementia: Pathology review
Developmental and learning disorders: Pathology review
Drug misuse, intoxication and withdrawal: Alcohol: Pathology review
Drug misuse, intoxication and withdrawal: Hallucinogens: Pathology review
Drug misuse, intoxication and withdrawal: Other depressants: Pathology review
Drug misuse, intoxication and withdrawal: Stimulants: Pathology review
Eating disorders: Pathology review
Malingering, factitious disorders and somatoform disorders: Pathology review
Mood disorders: Pathology review
Personality disorders: Pathology review
Psychiatric emergencies: Pathology review
Psychological sleep disorders: Pathology review
Schizophrenia spectrum disorders: Pathology review
Trauma- and stress-related disorders: Pathology review
Serotonin syndrome
0 / 8 complete
0 / 2 complete
of complete
of complete
2022
2021
2020
2019
2018
2017
2016
in serotonin syndrome p. 592
dextromethorphan p. 711
MAO inhibitors p. 599
MDMA p. 595
oxazolidinones p. 190
Serotonin syndrome is a potentially life-threatening condition that occurs when there is an excess of serotonin, a neurotransmitter in the brain, leading to a dangerous increase in nerve cell activity. Serotonin syndrome can occur as a result of taking certain medications, including selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs) or taking a combination of medications that increase serotonin levels. Symptoms include agitation, confusion, muscle rigidity and hyperreflexia, hypertension, dysrhythmias, diaphoresis, and tachypnea. Treatment may include discontinuing the culprit drug, supportive management, and providing cyproheptadine.
Copyright © 2023 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Cookies are used by this site.
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.